Panel to Review Siga Tech Smallpox NDA
Federal Register notice: FDA has announced a 5/1 Antimicrobial Drugs Advisory Committee meeting. Panel members are scheduled to discuss a Siga Technologies NDA for tecovirimat for the proposed indication of treating smallpox disease caused by variola virus in adults and pediatric patients. The product was developed under the agency’s Animal Rule (21 CFR part 314, subpart I). To view the notice, click here.